BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260416T080000
DTEND;TZID=America/New_York:20260416T093000
DTSTAMP:20260414T200719
CREATED:20260324T130051Z
LAST-MODIFIED:20260414T125857Z
UID:2955-1776326400-1776331800@lifescievents.com
SUMMARY:MeiraGTx Holdings Virtual KOL Event: Long-term data presentation for AAV-hAQP1 program for the treatment of Grade 2/3 Radiation-Induced Xerostomia
DESCRIPTION:The event will provide the full 3-year data from all cohorts of the open label Phase 1 study of MeiraGTx’s AAV-hAQP1 for the treatment of persistent grade 2/3 moderate to severe radiation-induced xerostomia (RIX)\, 3 or more years after curative radiation treatment for head and neck cancer. \nDr. Michael Brennan\, Atrium Health Carolinas Medical Center\, and Mr. David Owens\, University Hospital of Wales will discuss the unmet need and current treatment landscape. \nXerostomia (dry mouth) is a condition in which a person’s salivary glands do not produce enough saliva. Symptoms of persistent Grade 2/3 moderate to severe RIX include difficulty eating\, swallowing and chewing\, resulting in poor nutrition and potentially a feeding tube. Speaking and exercise can be impaired\, constant oral pain and infection and uncontrollable dental caries are also consequences of persistent RIX. AAV-hAQP1 is an investigational genetic medicine that is designed to improve xerostomia by increasing water flow in salivary glands damaged by radiation therapy for head and neck cancer. \nIn March 2026\, the FDA granted AAV-hAQP1 Breakthrough Therapy Designation. AAV-hAQP1 has also received Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Disease Designation (ODD). \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/q1ap38c/.
URL:https://lifescievents.com/event/q1ap38c/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/03/MeiraGTx-Banner.png
END:VEVENT
END:VCALENDAR